Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

NCT03710941 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The study was withdrawn due to an internal decision

Conditions

Sporadic Inclusion Body Myositis

Interventions

DRUG: REGN2477+REGN1033
DRUG: Matching placebo

Sponsor

Regeneron Pharmaceuticals